AU5721301A - Zolpidem hemitartrate - Google Patents

Zolpidem hemitartrate

Info

Publication number
AU5721301A
AU5721301A AU5721301A AU5721301A AU5721301A AU 5721301 A AU5721301 A AU 5721301A AU 5721301 A AU5721301 A AU 5721301A AU 5721301 A AU5721301 A AU 5721301A AU 5721301 A AU5721301 A AU 5721301A
Authority
AU
Australia
Prior art keywords
zolpidem hemitartrate
polymorphs
hemitartrate
zolpidem
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5721301A
Other languages
English (en)
Inventor
Ben-Zion Dolitzky
Marco Kordova
David Leonov
Erzebet Meszaros-Sos
Szaboles Salyi
Anchel Schwartz
Csaba Szabo
Shlomo Zavurov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU5721301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU5721301A publication Critical patent/AU5721301A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Amplifiers (AREA)
  • Supply Devices, Intensifiers, Converters, And Telemotors (AREA)
AU5721301A 2000-04-24 2001-04-24 Zolpidem hemitartrate Pending AU5721301A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19929800P 2000-04-24 2000-04-24
US20602500P 2000-05-22 2000-05-22
US22536400P 2000-08-14 2000-08-14
PCT/US2001/013175 WO2001080857A1 (en) 2000-04-24 2001-04-24 Zolpidem hemitartrate

Publications (1)

Publication Number Publication Date
AU5721301A true AU5721301A (en) 2001-11-07

Family

ID=27394001

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001257213A Ceased AU2001257213B2 (en) 2000-04-24 2001-04-24 Zolpidem hemitartrate
AU5721301A Pending AU5721301A (en) 2000-04-24 2001-04-24 Zolpidem hemitartrate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001257213A Ceased AU2001257213B2 (en) 2000-04-24 2001-04-24 Zolpidem hemitartrate

Country Status (21)

Country Link
US (8) US20020077332A1 (enExample)
EP (1) EP1292304B1 (enExample)
JP (3) JP2003531173A (enExample)
KR (1) KR20030069796A (enExample)
AT (4) ATE348613T1 (enExample)
AU (2) AU2001257213B2 (enExample)
CA (1) CA2406982A1 (enExample)
CZ (1) CZ20023775A3 (enExample)
DE (7) DE60125429T2 (enExample)
DK (1) DK1292304T3 (enExample)
ES (4) ES2239558T3 (enExample)
HR (1) HRP20020909A2 (enExample)
HU (1) HUP0300701A2 (enExample)
IL (1) IL152411A0 (enExample)
NZ (1) NZ522015A (enExample)
PL (1) PL358548A1 (enExample)
PT (3) PT1475093E (enExample)
SE (1) SE5292304T3 (enExample)
SK (1) SK16372002A3 (enExample)
WO (1) WO2001080857A1 (enExample)
YU (1) YU79402A (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001284322A1 (en) 2000-08-29 2002-03-13 Ranbaxy Laboratories Limited Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide, a key intermediate of zolpidem
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
ATE423116T1 (de) 2002-12-18 2009-03-15 Mallinckrodt Inc Synthese von heteroaryl acetamiden
WO2004087703A1 (en) * 2003-03-12 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of n,n,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide
EP1660496A1 (en) * 2003-07-31 2006-05-31 Ranbaxy Laboratories Limited Process for the synthesis of zolpidem
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
WO2006008636A2 (en) * 2004-07-16 2006-01-26 Ranbaxy Laboratories Limited Processes for the preparation of zolpidem and its hemitartrate
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070123562A1 (en) * 2005-05-25 2007-05-31 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the-night insomnia
ES2336142T3 (es) * 2005-08-19 2010-04-08 Aventis Pharmaceuticals Inc. Combinacion de un agente hipnotico y un compuesto sustituido, con bis arilo y heteroarilo y aplicacion terapeutica del mismo.
MX2008001705A (es) * 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y de r(+)-?-(2,3-dimetoxifenil) -1-[2-(4-fluorofenil)etil]-4-piperidimetanol y su aplicacion terapeutica.
US20080293946A1 (en) * 2005-10-03 2008-11-27 Cheng Brian K Process for Preparing Zolpidem Hemitartrate and Tartrate Polymorphs
US20080200680A1 (en) * 2005-10-17 2008-08-21 Cheng Brian K Polymorph Transformation of Zolpidem in Tablet Matrix
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
JP5066175B2 (ja) 2006-03-31 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリミジンおよびピラジン
US20080132535A1 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized Zolpidem Pharmaceutical Compositions
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
KR20110022721A (ko) * 2008-06-30 2011-03-07 얀센 파마슈티카 엔.브이. 벤조이미다졸-2-일 피리미딘 유도체의 제조 방법
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
EA201591648A1 (ru) * 2013-03-06 2016-02-29 Янссен Фармацевтика Нв Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
CN116283957A (zh) * 2021-12-03 2023-06-23 山东新时代药业有限公司 唑吡坦水合物及其制备方法
CN116283958A (zh) * 2021-12-03 2023-06-23 山东新时代药业有限公司 唑吡坦共晶体及其制备方法
CN117907368A (zh) * 2024-01-27 2024-04-19 鲁南贝特制药有限公司 一种酒石酸唑吡坦药用晶型d中晶型a、e的定量测定方法
CN118750459B (zh) * 2024-07-22 2025-04-01 常州市武进中医医院 一种酒石酸唑吡坦片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
IT1130924B (it) * 1980-03-06 1986-06-18 Secifarma Spa Procedimento per la preparazione di spironolattone micronizzato
DE3018940A1 (de) * 1980-05-17 1981-11-26 Hoechst Ag, 6000 Frankfurt Verwendung eines vinylchlorid-pfropf-copolymerisates in der plastisolverarbeitung
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
FR2525601A1 (fr) * 1982-04-21 1983-10-28 Synthelabo Derives d'imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4675323A (en) * 1985-08-06 1987-06-23 Synthelabo Imidazo(1,2-a)quinoline derivatives useful as anxiolytic agents
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
FR2600650B1 (fr) * 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
FR2606410B1 (fr) * 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
ES2026666T3 (es) * 1987-03-27 1992-05-01 Synthelabo Procedimiento para preparar derivados de imidazopiridinas.
US5271944A (en) * 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
IT1276522B1 (it) * 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
ES2195510T3 (es) * 1999-03-25 2003-12-01 Synthon Bv Derivados de imidazopiridina y procedimiento para prepararlos.
WO2000058310A1 (en) * 1999-03-25 2000-10-05 Synthon B.V. Zolpidem salts
WO2001042239A1 (en) * 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound

Also Published As

Publication number Publication date
WO2001080857A9 (en) 2002-06-27
DE60122944T2 (de) 2007-04-12
EP1292304A1 (en) 2003-03-19
ES2277301T3 (es) 2007-07-01
DE60125429T2 (de) 2007-09-27
US20040214858A1 (en) 2004-10-28
US20040214859A1 (en) 2004-10-28
ATE335481T1 (de) 2006-09-15
DE04010651T1 (de) 2005-09-01
ES2239558T1 (es) 2005-10-01
DE60114617D1 (de) 2005-12-08
IL152411A0 (en) 2003-05-29
WO2001080857A1 (en) 2001-11-01
JP2006249105A (ja) 2006-09-21
DE60125429D1 (de) 2007-02-01
DK1292304T3 (da) 2005-12-19
DE04010435T1 (de) 2005-09-01
YU79402A (sh) 2006-03-03
ES2239558T3 (es) 2007-04-01
EP1292304A4 (en) 2003-07-23
JP2006137778A (ja) 2006-06-01
PL358548A1 (en) 2004-08-09
AU2001257213B2 (en) 2005-09-29
ES2238941T3 (es) 2007-04-01
DE60114617T2 (de) 2006-07-27
PT1473036E (pt) 2006-10-31
US20020077332A1 (en) 2002-06-20
ES2238941T1 (es) 2005-09-16
CA2406982A1 (en) 2001-11-01
DE60122216T2 (de) 2007-08-30
HRP20020909A2 (en) 2004-08-31
PT1475093E (pt) 2006-11-30
SK16372002A3 (sk) 2003-04-01
JP2003531173A (ja) 2003-10-21
PT1541146E (pt) 2007-01-31
US20040220213A1 (en) 2004-11-04
HUP0300701A2 (hu) 2003-07-28
ES2248321T3 (es) 2006-03-16
EP1292304B1 (en) 2005-11-02
DE60122944D1 (de) 2006-10-19
DE20122435U1 (de) 2005-10-06
DE60122216D1 (de) 2006-09-21
US20040220212A1 (en) 2004-11-04
ATE348613T1 (de) 2007-01-15
US20040220211A1 (en) 2004-11-04
ATE308324T1 (de) 2005-11-15
CZ20023775A3 (cs) 2003-10-15
US20040220210A1 (en) 2004-11-04
ATE338550T1 (de) 2006-09-15
KR20030069796A (ko) 2003-08-27
US20070037843A1 (en) 2007-02-15
SE5292304T3 (enExample) 2005-11-02
NZ522015A (en) 2004-08-27

Similar Documents

Publication Publication Date Title
AU5721301A (en) Zolpidem hemitartrate
AU2003259226A1 (en) Preparation of 1h-imidazo(4,5-c)quinolin-4-amines via1h-imidazo (4,5-c)quinolin-4-phthalimide intermediates
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
AU3276802A (en) Background of the invention
AU3877500A (en) Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
JO2410B1 (en) 6. Replaced pyrido-pyrimidines
HUP0600592A2 (en) Substituted imidazopyridines, pharmaceutical compositions containing them and intermediates
MY130718A (en) Antitumor compounds and methods
MXPA03007834A (es) Uso de agonistas inversos de gabaa, en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
AU148078S (en) Bottle
PL368195A1 (en) Tricyclic imidazopyridines
MXPA04003755A (es) Endoprotesis vasculares.
AU6279500A (en) Epothilone compositions
MXPA04000541A (es) Formulacion liofilizada de 2-metil-tieno-benzodiazepina.
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
IL157607A0 (en) Methods for the preparation of mirtazapine intermediates
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
SI1594879T1 (sl) Postopek in intermediati za pripravo olanzapina
UA33933A (uk) Лімфогінний засіб
HK1071509A (en) Use of an ascomycin for the treatment of blepharitis
AU2002238815A1 (en) Device for the partial annealing of machined mechanical parts